Clinical Trials Sponsored by Merck KGaA, Darmstadt, Germany

Total 488 results

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...
Merck KGaA, Darmstadt, Germany

Completed

PK Study of Xevinapant (Debio 1143) in Healthy East Asian Participants

Healthy

United Kingdom
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...
Merck KGaA, Darmstadt, Germany

Completed

Study Comparing Pharmacokinetics of Different Formulations of Evobrutinib in Healthy Participants

Healthy

United Kingdom
Merck KGaA, Darmstadt, Germany

Completed

L-PZQ ODT in Schistosoma Infected Children

Schistosomiasis

Côte D'Ivoire, Kenya
Merck KGaA, Darmstadt, Germany

Completed

First-in-Human Trial of Single Ascending Dose, Multiple Ascending Dose and Malaria Challenge Model in Healthy Participants

Healthy

Australia
Merck KGaA, Darmstadt, Germany

Completed

Bioequivalence of TF3 and TF2 and Effect of Food on the PK of Tepotinib

Healthy

Germany
Merck KGaA, Darmstadt, Germany

Completed

Effect of a Proton Pump Inhibitor on the PK of Tepotinib

Healthy

Germany
Merck KGaA, Darmstadt, Germany

Completed

Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)

Non-small Cell Lung Cancer

Spain, Taiwan, Korea, Republic of, Singapore, China, Malaysia, Italy
Merck KGaA, Darmstadt, Germany

Completed

Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC

Squamous Non-Small Cell Lung Cancer

Spain, Hungary, Serbia
Merck KGaA, Darmstadt, Germany

Completed

Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor JPN)

Solid Tumors

Germany
Merck KGaA, Darmstadt, Germany

Completed

A Japanese Phase 1 Trial of c-Met Inhibitor MSC2156119J in Subjects With Solid Tumors

Solid Tumors

Japan
Merck KGaA, Darmstadt, Germany

Completed

Human Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]-Evobrutinib

Healthy

Netherlands
Merck KGaA, Darmstadt, Germany

Completed

A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients (TAILOR)

Metastatic Colorectal Cancer

China
Merck KGaA, Darmstadt, Germany

Completed

Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study of M5049 in Healthy Participants

Healthy

Germany
Merck KGaA, Darmstadt, Germany

Completed

Glucophage Immediate Release (GIR) China Bioequivalence Study

Healthy

China
Merck KGaA, Darmstadt, Germany

Completed

A Study to Assess the Food Effect on Bioavailability of Metformin/Gliclazide in Healthy Participants

Healthy

Mexico
Merck KGaA, Darmstadt, Germany

Completed

Bioequivalence Trial of Concor AM® vs Bisoprolol and Amlodipine in Chinese Participants

Healthy

China
Merck KGaA, Darmstadt, Germany

Completed

Matuzumab Treatment With Epirubicin, Cisplatin and Capecitabine (ECX) in Esophago-Gastric Cancer (MATRIX EG)

Gastric Cancer | Esophageal Cancer

Spain, United Kingdom, Switzerland, Germany
Merck KGaA, Darmstadt, Germany

Completed

A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis (RELIEF)

Multiple Sclerosis, Relapsing-Remitting

Germany
Merck KGaA, Darmstadt, Germany

Completed

A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis

Psoriasis | Candidates for Systemic Therapy for Psoriasis

Switzerland
Merck KGaA, Darmstadt, Germany

Completed

Safety and Efficacy of Pre-defined, Fixed Dose of Gonal-f Pen Based on Subject Baseline Characteristics in Subjects Undergoing in Vitro Fertilization (IVF) (CONSORT)

Infertility

France
Merck KGaA, Darmstadt, Germany

Completed

Relative Bioavailability Trial of L-Praziquantel in Healthy Volunteers

Healthy

Germany
Merck KGaA, Darmstadt, Germany

Completed

A Study to Determine the Safety, Tolerability, Pharmacokinetics and Dynamic Effects of Different Doses of the Study Drug EMD 525797 in Prostate Cancer

Prostate Cancer | Bone Metastases

Belgium, Germany
Merck KGaA, Darmstadt, Germany

Completed

Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX) (REFLEXION)

Multiple Sclerosis | Clinically Isolated Syndrome

Croatia, Bulgaria, France, Italy, Russian Federation, Spain, Estonia, Germany, Latvia, Poland, Romania, Argentina, Finland, Israel, Greece, Czech Republic, Slovakia, Austria, Belgium, Canada, Lebanon, Morocco, Portugal, Serbia
Merck KGaA, Darmstadt, Germany

Withdrawn

Anti-cancer MUC1-specific Immunotherapy for Unresectable Stage III Non-small Cell Lung Cancer (FINGERPRINT)

Non-small Cell Lung Cancer (NSCLC) Stage III
Merck KGaA, Darmstadt, Germany

Completed

Tecemotide (L-BLP25) in Rectal Cancer (SPRINT)

Rectal Cancer

Netherlands
Merck KGaA, Darmstadt, Germany

Completed

Atacicept in Combination With Rituximab in Subjects With Rheumatoid Arthritis (August III) (August III)

Rheumatoid Arthritis

Sweden, France, Netherlands, United Kingdom
Merck KGaA, Darmstadt, Germany

Completed

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment (SOLAR)

Relapsing-Remitting Multiple Sclerosis

Germany, Estonia, Latvia, Lithuania, Finland, Austria, Denmark, Netherlands, Portugal, Switzerland, Norway, Italy
Merck KGaA, Darmstadt, Germany

Terminated

Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population (INSPIRE)

Non-Small Cell Lung Cancer

Korea, Republic of, Taiwan, Singapore, China, Hong Kong
Merck KGaA, Darmstadt, Germany

Terminated

Common Safety Follow-up Trial of Tecemotide (L-BLP25)

Multiple Myeloma | Non-Small Cell Lung Cancer

Germany
Merck KGaA, Darmstadt, Germany

Terminated

Low-dose Gonal-f® in Ovulation Induction (LoGo)

Infertility | Monofollicular Development

United Kingdom, Ireland
Merck KGaA, Darmstadt, Germany

Terminated

Observational Study of Rebismart®2.0 + MSdialog™ in Subjects With Remitting Multiple Sclerosis (ADHERQOL) (ADHERQOL)

Multiple Sclerosis, Relapsing-remitting

Germany
Merck KGaA, Darmstadt, Germany

Completed

EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer (POSEIDON)

Metastatic Colorectal Cancer

Bulgaria, Czech Republic, Poland, Russian Federation, Spain, United Kingdom, Germany, Hungary, Belgium, Israel, Cyprus, Greece
Merck KGaA, Darmstadt, Germany

Completed

EMD 525797 in Colorectal and Ovarian Cancer Patients With Liver Metastases

Colorectal and Ovarian Cancer Patients With Liver Metastases

United Kingdom
Merck KGaA, Darmstadt, Germany

Completed

Phase 2b Randomized Controlled Study of Tecemotide (L-BLP25) for Immunotherapy of NSCLC (Non-Small Cell Lung Cancer)

Carcinoma, Non-Small-Cell Lung | Lung Neoplasms

Germany
Merck KGaA, Darmstadt, Germany

Completed

A Trial to Determine the Safety and Anti-tumor Activity Profile of the Combination of Cetuximab and Concomitant Cisplatin Plus 5-Fluorouracil (5-FU) in Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma in Head and Neck (CHANGE)

Squamous Cell Carcinoma of the Head and Neck

China, Korea, Republic of
Merck KGaA, Darmstadt, Germany

Completed

Pharmacogenetic Trial and Long-term Follow-up of the PRISMS Trial (PRISMS-15) (PRISMS-15)

Multiple Sclerosis

Switzerland
Merck KGaA, Darmstadt, Germany

Completed

To Identify and Evaluate the Predictive Factors for Depression in Patients Diagnosed With Multiple Sclerosis

Multiple Sclerosis

Argentina
Merck KGaA, Darmstadt, Germany

Completed

Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer (EXPAND)

Gastric Cancer

Brazil, Bulgaria, Czech Republic, France, Italy, Korea, Republic of, Poland, Russian Federation, Spain, United Kingdom, Germany, China, Hungary, Romania, Japan, Hong Kong, Argentina, Austria, Belgium, Chile, Israel, Greece, Taiwan, Au... and more
Merck KGaA, Darmstadt, Germany

Completed

A Prospective, Observational Study to Assess and Evaluate the Use of Glucophage XR Therapy in the Management of Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Singapore
Merck KGaA, Darmstadt, Germany

Completed

An Observational Study Comparing Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL) and Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) in Relapsing Multiple Sclerosis (RMS) Patients on Long-term Rebif® Therapy (COMPARE)

Multiple Sclerosis, Relapsing-Remitting
Merck KGaA, Darmstadt, Germany

Completed

A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis (IMPROVE)

Multiple Sclerosis, Relapsing-Remitting
Merck KGaA, Darmstadt, Germany

Completed

A Postmarketing Surveillance (PMS) Study to Evaluate the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis (MS) With Interferon Beta 1a (Rebif®) (TOURIMS)

Relapsing-Remitting Multiple Sclerosis
Merck KGaA, Darmstadt, Germany

Completed

Study of Cetuximab With Concomitant-boost Radiotherapy in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Carcinoma of the Head and Neck

Japan
Merck KGaA, Darmstadt, Germany

Completed

Evaluation of Convenience and Compliance of the Easypod™ Electronic Self-injector

Growth Hormone Deficiency | Chronic Renal Failure | Turner Syndrome | Small for Gestational Age
Merck KGaA, Darmstadt, Germany

Completed

A Observational, Prospective Study to Assess the Impact of Fatigue in the Quality of Life of Patients With Multiple Sclerosis in Argentina

Multiple Sclerosis, Relapsing-remitting

Argentina
Merck KGaA, Darmstadt, Germany

Completed

Transition to Rebif New Formulation (TRANSFER)

Relapsing Multiple Sclerosis

France, Germany
Merck KGaA, Darmstadt, Germany

Completed

Long Term Follow up Study of Predictive Markers in GHD and TS Children (PREDICT LT FUP)

Growth Hormon Deficiency | Turner Syndrome in Pre-pubertal Children
Merck KGaA, Darmstadt, Germany

Completed

An Observational Study to Assess the Quality of Life of the Patients With Multiple Sclerosis and Their Caregivers

Multiple Sclerosis

Argentina
Merck KGaA, Darmstadt, Germany

Terminated

Raptiva in Palm and Sole Psoriasis

Chronic Plaque Psoriasis
Merck KGaA, Darmstadt, Germany

Completed

Cetuximab and Cisplatin in the Treatment of "Triple Negative" (Estrogen Receptor [ER] Negative, Progesterone Receptor [PgR] Negative, and Human Epidermal Growth Factor Receptor 2 [HER2] Negative) Metastatic Breast Cancer (BALI-1)

Breast Neoplasm

Spain, United Kingdom, Germany, Australia, Austria, Belgium, Israel, New Zealand, Portugal, Italy, Ireland

3

Subscribe